食品伙伴網(wǎng)訊 2022年8月8日,歐盟食品安全局就一種凝乳酶(chymosin)的安全性評價發(fā)布意見。
經(jīng)過評估,專家小組認為,在預期的使用條件下,不能排除飲食暴露引起過敏和誘發(fā)反應的風險,特別是對雪松花粉過敏原過敏的個體。根據(jù)所提供的數(shù)據(jù),評估小組得出結論,這種食品酶在預期使用條件下不會引起安全問題。部分原文報道如下:
The food enzyme chymosin (EC 3.4.23.4) is produced with the genetically modified Kluyveromyces lactis strain CHY by DSM Food Specialties B.V. It is intended to be used in milk processing for cheese production and for production of fermented milk products. Dietary exposure was estimated to be up to 0.69 mg total organic solids (TOS)/kg body weight (bw) per day in European populations. The production strain contains multiple copies of known antimicrobial resistance genes and consequently, it does not fully fulfil the requirements for the qualified presumption of safety (QPS) approach to safety assessment. However, considering the absence of viable cells and DNA from the production organism in the food enzyme, this is not considered to be a risk. As no other concerns arising from the microbial source and its subsequent genetic modification or from the manufacturing process have been identified, the Panel considered that toxicological tests were not needed for the assessment of this food enzyme. Similarity of the amino acid sequence of the food enzyme to those of known allergens was searched and four matches were found. The Panel considered that, under the intended conditions of use, the risk of allergic sensitisation and elicitation reactions by dietary exposure, although unlikely, cannot be excluded, particularly for individuals sensitised to cedar pollen allergens. based on the data provided, the Panel concluded that this food enzyme does not give rise to safety concerns under the intended conditions of use.
本文由食品伙伴網(wǎng)食品資訊中心編輯,有任何疑問,請聯(lián)系news@foodmate.net。